aging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the syringe.

2. The pharmaceutical packaging system of claim **1**, wherein the syringe is plastic or glass.

3. The pharmaceutical packaging system of claim **1**, wherein the blister packaging is an aluminum-based cold formed blister, or a molded blister.

4. The pharmaceutical packaging system of claim **1**, wherein the oxygen absorber is placed inside the blister packaging.

5. The pharmaceutical packaging system of claim **1**, wherein the oxygen absorber is a canister.

6. The pharmaceutical packaging system of claim **1**, wherein the oxygen absorber has a capacity to absorb about 30 cc oxygen at 1 atm.

7. The pharmaceutical packaging system of claim **1**, wherein the oxygen absorber is iron-based.

8. The pharmaceutical packaging system of claim **1**, wherein the oxygen absorber reduces the oxygen level in the blister packaging from the time of packaging assembly to about zero percent at about one day.

9. The pharmaceutical packaging system of claim **1**, wherein the oxygen absorber reduces the oxygen level in the syringe from the time of packaging assembly to about zero percent at about one month.

10. The pharmaceutical packaging system of claim **1**, wherein the oxygen level remains at about zero percent in the syringe and the blister packaging for at least three years.

11. The pharmaceutical packaging system of claim **1**, wherein the injectable oxygen-sensitive drug is morphine.

12. The pharmaceutical packaging system of claim **1**, wherein the injectable oxygen-sensitive drug is hydromorphone.

13. The pharmaceutical packaging system of claim **1**, wherein the injectable oxygen-sensitive drug is promethazine.

14. The pharmaceutical packaging system of claim **1**, wherein the blister packaging is a thermoformed blister.

15. A pharmaceutical packaging system for injectable morphine, the packaging system comprising:

(i) a syringe filled under inert conditions with morphine, wherein the syringe has an oxygen permeable tip cap,

(ii) a hermetically sealed oxygen barrier blister packaging which houses the syringe, wherein the blister packaging comprises a multilayer bottom web comprising ethylene vinyl alcohol (EVOH) and a multilayer top web lid comprising aluminum foil or EVOH; and

(iii) an oxygen absorber, wherein the oxygen absorber reduces the oxygen level from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the syringe.

16. A pharmaceutical packaging system for injectable hydromorphone, the packaging system comprising:

(i) a syringe filled under inert conditions with hydromorphone, wherein the syringe has an oxygen permeable tip cap,

(ii) a hermetically sealed oxygen barrier blister packaging which houses the syringe, wherein the blister packaging comprises a multilayer bottom web comprising ethylene vinyl alcohol (EVOH) and a multilayer top web lid comprising aluminum foil or EVOH; and

(iii) an oxygen absorber, wherein the oxygen absorber reduces the oxygen level from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the syringe.

17. A pharmaceutical packaging system for injectable promethazine, the packaging system comprising:

(i) a syringe filled under inert conditions with promethazine, wherein the syringe has an oxygen permeable tip cap,

(ii) a hermetically sealed oxygen barrier blister packaging which houses the syringe, wherein the blister packaging comprises a multilayer bottom web comprising ethylene vinyl alcohol (EVOH) and a multilayer top web lid comprising aluminum foil or EVOH; and

(iii) an oxygen absorber, wherein the oxygen absorber reduces the oxygen level from the time of packaging assembly to about zero percent in about one to three days in the blister packaging and in about one to three months in the syringe.

* * * * *